EPI-321

EPI-321 is an investigational, first-in-class epigenetic therapy being developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. The therapy is designed as a potential one-time gene-modulating treatment that silences aberrant expression of the DUX4 gene, which is incorrectly activated in FSHD and leads to progressive muscle degeneration. EPI-321 utilizes a catalytically inactive Cas protein (dCas) fused to gene-suppressing modulators, delivered systemically via an adeno-associated virus vector (AAVrh74). Its mechanism involves restoring methylation to the D4Z4 region on chromosome 4, thereby blocking toxic production of DUX4 protein in muscle cells and reducing cell death. Preclinical studies have shown robust suppression of DUX4 expression and increased survival of skeletal muscle cells. The drug has received FDA Orphan Drug Designation, Fast Track designation, and Rare Pediatric Disease designation for FSHD[1][2][3][6].